The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple ...

Spokane may be hundreds of miles from major academic medical centers, but its becoming a national leader in an advanced ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES By Aktis Oncology May 28, 2025 Updated 51 ...

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES Provided by PR Newswire May 28, 2025, 4:00:00 AM ...

BOISE, Idaho — Plans are underway for a "Hetero Awesome Fest" on June 20-21, 2025, in Cecil D. Andrus Park, located directly in front of Idaho's Capitol building in Boise. The event, organized ...